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In view of the unclear prognostic and diagnostic role of interleukin 2 (IL-2) and
its receptor in human tumours, we examined the cellular expression of IL-2 and
of the subunit a of its receptor (IL-2Ra, CD25) in relation to the proliferative
activity of various subtypes of lung tumours. The immunocytochemical ABC tech-
nique was applied to archival tissue material of neuroendocrine lung tumours:
lung carcinoids, including typical carcinoids (TC), atypical carcinoids (AC) and
small-cell lung cancers (SCLC) and squamous cell lung cancers (non-small cell
lung cancers, NSCLC). Expression of IL-2 was detected in all types of lung tu-
mours. The highest frequency of IL-2 expression (93%) was noted and the most
pronounced semi-quantitatively evaluated expression of IL-2 was detected in
AC tumour cells. The expression was more pronounced as compared to neo-
plastic SCLC (p = 0.01) and NSCLC cells (p = 0.005). The results suggest
a negative correlation between IL-2 expression and the proliferative activity of
tumour cells (evaluated by expression of Ki-67) in AC. The frequency of detec-
tion of IL-2 receptor (IL-Ra, CD25) was the highest in NSCLC (94%). Semi-quan-
titative expression of IL-2R, like that of IL-2, also dominated in the group of
atypical lung carcinoids but manifested a significant difference only as com-
pared to typical carcinoids (p = 0.014). Within the groups of tumours studied
no correlation could be detected between cellular expressions of IL-2 and IL-2R.
Our results demonstrate variable expression of IL-2 and its receptor in various
types of lung tumours, but no simple relationship could be detected between
tissue expression of the markers and proliferative activity. Appraisal of the diag-
nostic and/or prognostic significance of the results requires further study.
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INTRODUCTION
Primary lung cancer is at present the most fre-
quently diagnosed type of tumour and one of the
principal causes of human death worldwide. Inci-
dence and mortality due to lung cancer manifest
rising tendencies, particularly in the developing
countries [20].
The interest of investigators in interleukin 2 (IL-2)
and its receptor (IL-2R) is linked, first of all, to tu-
mour immunotherapy and syndromes associated
with immune defects (e.g. AIDS) [10, 14]. Modified
human IL-2 obtained by genetic engineering acts in
a similar way to human endogenous IL-2. It strongly
stimulates immune responses (lymphocytes T),
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augments the proliferation and activity of cytotoxic
NK cells, and increases the release of other cytokines
(e.g. TNF, IL-1) by monocytes and macrophages [18,
19, 27]. Nevertheless, the final results of anti-neoplas-
tic therapy with IL-2 remain far from satisfactory. Most
studies have demonstrated production of IL-2 by im-
munocompetent cells isolated from the blood of tu-
mour-bearing patients. The results have frequently
been incoherent or contradictory. Few of the investi-
gators have focused their attention on the tissue ex-
pression of IL-2 and its receptor and their reciprocal
relationship. It also remains unclear why IL-2 inhib-
its growth of certain cells of human tumours, while
the proliferation of others continues in parallel with
similarly pronounced expression of IL-2Rb in their cell
membranes. It has been suggested that the endog-
enous IL-2 has, like other growth factors and hor-
mones, been involved in growth control in tumour
cells [12]. Opinions have also been expressed that
endogenous IL-2 stimulates tumour cell proliferation
(in squamous cell carcinomas of the head and neck)
and that inhibition of tumour growth can be ob-
tained using anti-sense IL-2 [23].
Studies on the role of the receptor for IL-2, and
the soluble form of its subunit a (sIL-2R) in particu-
lar, have mainly involved measurements of their se-
rum levels in patients [13–15]. Recent studies have
focused on the determination of correlations be-
tween IL-2Ra expression and the growth of tumour
cells in vivo [10]. The results of these studies have
shown that over-expression of IL-2Ra is responsible
for stimulated proliferation of tumour cells [26, 28].
Numerous investigators have demonstrated over-
expression of IL-2Ra in tumours, including cancers
of the lung, skin, prostate and oesophagus, and in
leukaemias [10, 11]. One of the mechanisms of
growth promotion in tumour cells by IL-2Ra is sup-
posed to involve inhibition of apoptosis [22, 25].
Most of the studies on IL-2 in lung tumours have
pertained to non-small cell lung cancers (NSCLC)
studied either in vitro or in vivo [4, 12, 14, 29]. How-
ever, production of the cytokine was studied mainly
in blood immunocompetent cells (lymphocytes,
monocytes). In general, a suppression of the secre-
tion of selected cytokines, which is dependent upon
the clinical advancement of the lung tumour, has
been noted [5]. Moreover, decreased IL-2 produc-
tion has been demonstrated to correlate with the
duration of patient survival and it has been suggest-
ed that decreased IL-2 production at the moment of
SCLC diagnosis provides an important independent
prognostic factor.
In general, in studies on the receptor for IL-2
(IL-2R) in lung tumours elevated serum levels of sIL-2R
have been noted. This finding has correlated with
the progression of the tumour and with the aggres-
siveness of the disease and, in some studies, with
decreased levels of IL-2 itself [4, 13, 16]. On the oth-
er hand, attempts to establish a relationship between
serum sIL-2R levels and respective levels of IL-2Ra
(Tac molecule, CD25) in lung tumour tissue have had
divergent results. The roles of IL-2 and its receptor,
produced by the tumour cells themselves, have re-
mained poorly defined.
In view of the incomplete clarification of the
reasons for the ineffective therapy of lung tu-
mours and the irreproducibility of data on cyto-
kine expression by tumour cells, we decided to
examine tissue expression of IL-2 and its receptor
(IL-2Ra, CD25) in histologically different types of
lung tumour.
MATERIAL AND METHODS
The material for the studies included buffered
formalin-fixed paraffin-embedded histologically
different subtypes of lung tumours: typical (TC)
(n = 14) and atypical lung carcinoids (AC) (n = 8),
small-cell (SCLC) (n = 24), and squamous cell lung
cancers (the NSCLC group of tumours) (n = 17).
The material was histopathologically evaluated by
two independent pathomorphologists. The posi-
tive control material involved reactive lymph nodes
from patients free of neoplastic disease (n = 15).
In studies on the tissue material routine staining
techniques for histopathological examination were
used, including haematoxylin and eosin, silver im-
pregnation and immunocytochemistry. The avidin-
biotin peroxidase complex (ABC) technique was
employed [8] with the use of monoclonal mouse
antibodies (MAbs) to human IL-2 at the dilution
of 1:100 (R&D Systems) and to human CD25
(IL-2Ra) at the same dilution (NOVOCASTRA), as
well as MAbs to human Ki-67 antigen (clone MIB-1)
at the dilution of 1:2 (DAKO). The colour reaction
was evoked with the horseradish peroxidase sub-
strate, 0.05% DAB in 0.05 M Tris-HCl buffer, pH
7.6, supplemented with 0.001% H202. A positive
reaction was manifested in at least three sequen-
tial sections as a dark brown or black precipitate
in the cell membranes, cell nucleus and/or cyto-
plasm. Control reactions employed control sera of
the respective species in 0.05 M Tris-HCl, pH 7.6,
supplemented with 0.1% BSA and 15 mM sodium
azide (negative control).
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Semi-quantitative evaluation of the
results and statistics
The intensity of expression of IL-2 and IL-2R
(CD25) proteins in lung cancers obtained using ABC
was estimated by the use of the semi-quantitative
IRS scale according to Remmele and Stegner [24],
taking into account the intensity of the colour reac-
tion and the number of positive cells. The final score
represented the product of the scores representing
the two variables and ranged from 0 to 12 points. In
each preparation 10 visual fields were appraised at
a total magnification of 400x, and mean scores were
calculated (Table 1). Expression of Ki-67 prolifera-
tive antigen (nuclear reaction) was calculated, tak-
ing into account the mean percentage of immunop-
ositive cells in 10 visual fields of a light microscope.
The expression was defined in line with the modi-
fied semi-quantitative scale of Gatter et al. [7], where
a score of 1 denoted up to 10% of cells with a pos-
itive reaction and scores of 2, 3 and 4 corresponded
to, respectively, 11–25%, 26–50% and ≥ 51% cells
with a positive reaction. All the preparations were
examined with an OLYMPUS B-2 light microscope.
In order to determine the statistical signifi-
cance of variations in the intensity of expression of
the investigated proteins and the Ki-67 antigen we
first calculated the mean values of the staining scores
in each group of lung cancers. The means were com-
pared using the Mann-Whitney U test for non-para-
metric independent data. Correlations between data
rows were determined employing Spearman’s rank
correlation index. A p value below 0.05 was assumed
to indicate significant difference.
RESULTS
Cellular expression of Ki-67 antigen in
lung tumours
Expression of Ki-67 proliferation antigen involved
exclusively cell nuclei of neoplastic cells (Fig. 1A, B).
The number of immunopositive cell nuclei varied in
individual types of lung tumour (Table 2). The signif-
icantly lowest proliferative activity was demonstrat-
ed by typical lung carcinoids as compared to the re-
maining groups of tumours; AC, SCLC and NSCLC did
not differ significantly in the expression of Ki-67 anti-
gen (Fig. 4). In the control material (non-neoplastic
lesions) individually labelled cell nuclei were observed
in germinal centres of the lymphoid follicles.
Cellular expression of interleukin-2 in
lung tumours
Cellular expression of IL-2 was demonstrated in
all four types of lung tumour studied. It was docu-
mented in 13/14 (93%) typical carcinoids, in 7/8
(88%) atypical lung carcinoids, in 21/24 (88%) small
cell and in 13/17 (76%) squamous cell lung carcino-
mas. Marked individual differences were observed
in IL-2 expression in individual patients (Table 2). IL-2
was detected in the cytoplasm of tumour cells and
the most evident cytoplasmic reaction was detected
in the cells of typical lung carcinoids (Fig. 2A, B). IL-2
expression was also visible in the cells of inflamma-
tory infiltrates which accompanied lung tumours, but
such cells were not subjected to semi-quantitative
evaluation in the present study. Semi-quantitative-
ly, the most pronounced expression of IL-2 was de-
tected in tumour cells of atypical carcinoids and it
was significantly higher than the expression noted
in SCLC (p = 0.01) or NSCLC (p = 0.005). Moreover,
a tendency was observed for expression of IL-2 in
cells of TC to be augmented in comparison with those
in NSCLC (p = 0.058) (Fig. 5).
In the control material (non-neoplastic lesions)
expression of IL-2 was seen mainly in lymphocytes T
and macrophages/monocytes within inflammatory
lesions in the lymph nodes.
Cellular expression of the subunit a of the IL-2
receptor (IL-2Ra, CD25) in lung tumours
Immunocytochemical studies have demonstrat-
ed expression of IL-2Ra (CD25) in 5/14 (36%) cases
Table 1. Evaluation of IL-2 and IL-2R (CD25) expression in
the studied preparations according to Remmele and Steg-
ner [24]. The final score represents a product of the posi-
tive cell score (A) and the score reflecting the intensity of
the colour reaction (B)
A
0: no cells with positive reaction
1: to 10% cells with positive reaction
2: 11 to 50% cells with positive reaction
3: 51 to 80% cells with positive reaction
4: > 80% cells with positive reaction
B
0: no colour reaction
1: low intensity of colour reaction
2: average intensity of colour reaction
3: intense colour reaction
No reaction: score 0 points; weak reaction: score 1 to 2 points; average intensity
of the reaction: score 3 to 4 points; intense reaction: score 6 to 12 points
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Figure 1. A. Small-cell lung carcinoma. Numerous MIB-1-positive (Ki-67 antigen) in cell nuclei. Patient no. 4; B. Immunocytochemical
localisation of Ki-67 in typical lung carcinoid. Patient no. 10. ABC technique. All bar markers represent 20 µm.
Figure 2. A. Immunocytochemical localisation of IL-2 in typical lung carcinoid. Patient no. 2. ABC technique; B. Immunocytochemical
localisation of IL-2 in squamous cell lung carcinoma. Patient no. 9. ABC technique. Counterstained with haematoxylin (B). All bar markers
represent 20 µm.
Figure 3. A. Immunocytochemical localisation of IL-2Ra (CD25) in squamous cell lung carcinoma. Note the membranous localisation of
CD25. Patient no. 10; B. Cytoplasmic and membranous localisation of IL-2Ra (CD25) in squamous cell lung carcinoma. Patient no. 6.
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Table 2. Semi-quantitative evaluation of Ki-67 antigen, IL-2 and IL-2R expression in patients with different types of lung
carcinoma according to Remmele and Stegner [24]
Patient (no.)              Typical carcinoid                 Atypical carcinoid SCLC NSCLC
Ki-67 IL-2 IL-R Ki-67 IL-2 IL-R Ki-67 IL-2 IL-R Ki-67 IL-2 IL-R
1 1 6 3 2 12 10 4 0 0 3 3 3
2 2 12 0 1 9 0 4 2 0 4 3 3
3 2 3 0 4 12 6 2 2 0 2 6 0
4 2 4 0 3 8 3 4 2 3 3 3 3
5 1 12 12 4 0 3 1 4 0 3 3 6
6 1 12 0 4 6 4 3 3 0 4 6 3
7 1 3 4 4 6 6 4 6 6 4 0 6
8 1 3 0 4 6 10 4 0 6 4 6 8
9 2 6 0 3 3 4 3 6 3
10 1 1 0 3 6 3 4 3 4
11 1 2 0 3 4 6 4 3 4
12 1 6 0 1 6 4 3 0 3
13 2 0 3 4 2 2 3 0 6
14 1 8 3 3 6 6 3 2 3
15 4 3 2 3 0 3
16 1 3 3 4 3 6
17 4 0 4 4 2 2
18 4 6 0
19 3 6 6
20 4 6 0
21 4 6 0
22 4 8 10
23 4 3 6
24 4 6 0
SCLC — small-cell lung carcinoma; NSCLC — non-small cell lung carcinoma (squamous cell lung carcinoma)
Figure 5. Expression of IL-2 on the semi-quantitative 12-point
IRS scale [24] as related to histological type of lung tumour;
TC — typical lung carcinoid; AC — atypical lung carcinoid;
SCLC — small-cell lung carcinoma; NSCLC — non-small cell lung
carcinoma (squamous cell lung carcinoma); *p = 0.058 for TC vs.
NSCLC; **p = 0.01 for AC vs. SCLC; p = 0.005 for AC vs. NSCLC.
Figure 4. Average expression of Ki-67 antigen in studied groups
of lung tumours on the four-point scale of Gatter et al. [7]; TC —
typical lung carcinoid; AC — atypical lung carcinoid; SCLC —
small-cell lung carcinoma; NSCLC — non-small cell lung carcino-
ma (squamous cell lung carcinoma); *p = 0.001 for TC vs. AC;
p = 0.00001 for TC vs. SCLC and p = 0.000002 for TC vs. NSCLC.
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of typical lung carcinoids. In atypical lung carcinoids
expression of IL-2R was shown in the same propor-
tion of patients as demonstrated expression of IL-2
(88%). In SCLC expression of IL-2R pertained to 15/24
(62%) cases. The most frequent tissue expression of
IL-2R was detected in squamous cell lung cancers
(94%) (Table 2). The product of the immunocy-
tochemical reaction was observed in diffusely spread
or focally arranged cells within their cell membranes
and cytoplasm (Fig. 3A, B). In semi-quantitative com-
parisons of IL-2R expression using the IRS scale, as
with the IL-2 expression, it was most pronounced in
the atypical lung carcinoid group but differed sig-
nificantly only when compared with the typical lung
carcinoids (p = 0.014) (Fig. 6). A significantly lower
expression of IL-2R was found in typical lung carci-
noids, in comparison both with AC (p = 0.014) and
NSCLC (p = 0.004).
In the control material (non-neoplastic lesions),
IL-2Ra was detected in scattered or grouped cells of
mainly T lymphocytes.
Correlations between reciprocal expression of
IL-2 and IL-2R and between the expression of
both markers and Ki-67
Spearman’s correlation could not be detected
between expressions of IL-2 and IL-2R in any of
the types of lung tumour. In addition, no signifi-
cant relationships could be detected between ex-
pression of IL-2 and its receptor and the cellular
expression of the Ki-67 proliferation antigen in the
groups of tumours studied. Only in the AC group
was a tendency noted for a negative correlation
between the expression of IL-2 and that of Ki-67 antigen
(r = –0.590), although this relationship was statisti-
cally insignificant (p = 0.123).
DISCUSSION
Interleukin-2 participates in graft rejection and
its action is probably local in character. After the in-
jection of cells with transfected IL-2 an exclusively
local inhibition of tumour cell growth was noted at
very low serum levels of IL-2 [17]. IL-2 induces anti-
tumour activity by increasing numbers of NK and
MHC-restricted tumour-specific cytotoxic cells [10].
Moreover, a plethora of secondary cytokines is in-
duced in the response to IL-2 in vivo [18]. Some au-
thors have reported that direct effects of IL-2 on tu-
mour cells could not be noted [21]. In advanced stag-
es of several malignant tumours decreased produc-
tion of IL-2 by lymphocytes and a decreased expres-
sion of receptors for IL-2 on cytotoxic cells have been
noted [14]. Data on the secretion of IL-2 and its re-
ceptor by tumours cells are incomplete. Most such
studies were performed on NSCLC [4, 7, 9, 12].
Our studies, comprising four subtypes of lung
tumour, demonstrated differences in the cellular
expression of IL-2 depending on the histological sub-
type of lung tumour. The exclusively cytoplasmic
expression of IL-2 was noted in tumour cells. The
semi-quantitatively most pronounced expression was
detected in atypical lung carcinoids, neuroendocrine
lung tumours of worse prognosis in relation to sur-
vival than typical lung carcinoids [31]. No significant
relationship was established between IL-2 expression
and the intensity of proliferative activity (expression
of Ki-67 antigen) and a tendency was noted for
a negative correlation between the two parameters
only in atypical lung carcinoids (r = –0.591; p > 0.05).
The low number of cases in the group (n = 8) made
the result insignificant. It remains difficult to com-
ment on the observations of some investigators re-
garding whether expression of endogenous IL-2 in
squamous cell cancers of the neck and head is re-
quired for the proliferation of tumour cells [23]. The
least pronounced expression of IL-2 was detected in
pulmonary squamous cell cancers, which could indi-
cate that production of the cytokine is suppressed
in this type of tumour and may provide an ominous
prognostic factor. Selective suppression of cytokine
release was reported in lung cancers (IL-2, IFN-a and
IFN-g), depending upon tumour size and variably ex-
pressed in individual patients with SCLC and NSCLC [5].
In our studies no significant differences were noted
in the tissue expression of IL-2 between SCLC and
NSCLC. Some studies have pointed to a complete
Figure 6. Expression of IL-2 receptor (IL-2R) on the semi-quanti-
tative 12-point IRS scale [24] as related to histological type of
lung tumour; TC — typical lung carcinoid; AC — atypical lung
carcinoid; SCLC — small-cell lung carcinoma; NSCLC — non-
-small cell lung carcinoma (squamous cell lung carcinoma).
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absence of IL-2 and IFN-g secretion in NSCLC both in
vitro, and in vivo [9]. Some authors have observed
a correlation between shorter survival in advanced
pulmonary cancers and a decreased IL-2 level in se-
rum [14]. Not having access to full data on the pa-
tients, we cannot comment on the results.
Over-expression of IL-2Ra has been demonstrat-
ed in several human tumours, including cancers of
the lungs, skin, prostate and oesophagus and in leu-
kaemias [10, 11]. It is assumed that IL-2Ra-positive
cells proliferate more rapidly and manifest chromo-
somal instability, which may promote enhanced ag-
gressiveness of the tumour, more pronounced resis-
tance to drugs and worsen the prognosis [6, 10, 11].
Our results demonstrated the presence of the
IL-2a chain (CD25, Tac molecule) in all subtypes of
lung tumour, although to a variable extent with re-
spect to frequency and the intensity of its expres-
sion. CD25 was located exclusively in the cell mem-
branes of tumour cells. The most frequent presence
of IL-2R was demonstrated in the group of squa-
mous cell lung cancers and the least frequent in typ-
ical lung carcinoids. In semi-quantitative appraisal,
the highest expression of both IL-2R and IL-2 pro-
teins was detectable in the atypical lung carcinoids.
Data in the literature provide evidence for the pres-
ence of functional IL-2R in the cultured cells of hu-
man squamous cell cancer of the head and neck [30].
However, immunofluorescence studies of cultured
cells of SCLC did not show expression of IL-2Ra chain
on their surface [17]. Analysis of serum levels of the
so-called “soluble” form of IL-2R (sIL-2R), particular-
ly in non-small cell lung tumours, demonstrated ele-
vated levels of this as compared to the control. This
correlated with the progression of the tumour and
aggressiveness of the disease and, in some studies,
also with decreased levels of IL-2 itself [4, 13, 16].
However, findings on a correlation between sIL-2R
and its equivalent in tumour tissue (i.e. IL-2Ra) are
incoherent. Some authors have demonstrated posi-
tive [16] and others a negative correlation between
concentrations of sIL-2R and Tac-positive cells [4, 13].
In our own study no significant relationships could
be detected between the expression of IL-2 and the
expression of its receptor at the tissue level in any of
the tumour types studied.
Evaluation of tumour proliferative activity is
thought to predict the clinical course of the tumour
and may serve as an additional diagnostic index.
Several approaches can be used for the evaluation
of a tumour cell proliferative index [2]. One of these
involves the immunocytochemical expression of the
Ki-67 antigen using monoclonal antibodies [2, 7].
The Ki-67 antigen is present at any stage of the cell
cycle (except G0) and in histological preparations the
staining pertains to dividing cell nuclei [7]. Co-local-
isation of the antigen has been demonstrated with-
in peri-nucleolar chromatin and the role of the anti-
gen is suggested in the higher-order organisation of
this [3]. In the present study, as expected, the most
numerous dividing cells, evaluated by their anti-Ki-67
staining, were detected in SCLC and squamous cell
lung cancers, and also in atypical pulmonary carci-
noids. In agreement with the literature data, the low-
est number of dividing cells was found in typical lung
carcinoids [1]. The same authors observed a nega-
tive correlation between proliferative activity and the
duration of survival [1]. In our study we used the
detection of Ki-67 antigen for the examination of
a potential relationship between IL-2Ra and the cell
proliferation index in various types of lung tumour.
However, in none of the studied tumour types was
such a correlation demonstrable.
CONCLUSION
In summary, in the present studies we found
expression of IL-2 and the a chain of its receptor
(IL-2Ra) both in neuroendocrine lung tumours (typ-
ical and atypical pulmonary carcinoids and small-cell
lung cancer) and in non-small cell lung cancers (squa-
mous cell lung cancers). The most frequent detec-
tion of IL-2 was observed in typical lung carcinoids
(93%), and IL-2R expression was most frequent in
squamous cell lung cancers (94%). However, the
expression of IL-2 and its receptor were not correlat-
ed. Moreover, in most cases the occurrence of IL-2
and IL-2R also failed to show any relationship with
the expression of Ki-67, used in this study as an in-
dex of cell proliferation. Semi-quantitative analysis
demonstrated the most pronounced expression of
IL-2 in atypical pulmonary carcinoids. Additional
studies are necessary to confirm the negative corre-
lation between IL-2 expression and the proliferation
index of the neoplastic cells reported by other au-
thors [5]. The most pronounced semi-quantitatively
evaluated expression of IL-2R was also documented
for atypical carcinoids, although this was not corre-
lated with a tumour’s proliferative activity.
The diagnostic and prognostic significance of our
results requires further study.
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